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Introdution
 The clinical course of myocardial infarction frequently burdened by a 
variety of complications, which largely determine its course and 
prognosis
 Complications of acute MI are different and life threatening
 If a person survives the sudden loss by ischemic necrosis of part of 
the ventricular muscle there follows a period in which special dangers 
threaten each of the physical systems and the personality itself 
 These dangers arise from two principal sources; on the one hand, from 
the local effects of the lesion and the circulatory depression that 
follows; and, on the other, from the hazards that may attend during 
active treatment
 The onset of each of these complications usually results in explicit 
symptoms and physical manifestations; thus, a basic knowledge of the 
complications that occur in the postinfarction period and the clinical 
syndromes associated with each, will allow the physician to evaluate 
and treat the complication appropriately 
 Prompt diagnosis and therapy are essential
Goal
The purpose of this presentation is to introduce to 
the complications that may arise in the course of 
acute MI and demonstrate that various therapeutic 
modalities, both medical and surgical, should be 
able to improve not only symptoms but also 
survival of the patient
Definition
Acute myocardial infarction (MI) defines 
cardiomyocyte necrosis in a clinical setting 
consistent with acute myocardial ischaemia 
CLASSIFICATION
Mechanical 
Arrhythmic 
 Ischemic 
 Inflammatory 
Embolic 
Complications Of MI
Mechanical Complications of MI
CLASSIFICATION
 Left ventricular failure and cardiogenic shock 
 Ventricular free wall rupture (VFWR)
 Ventricular septal rupture (VSR)
 Papillary muscle rupture with severe mitral regurgitation (MR)
 Ventricular aneurysm 
RISK FACTORS
- age older than 60 years
- female gender
- pre-existing hypertension
- lack of left ventricular hypertrophy
- and no previous MI (pre-existing scarring tends to prevent myocardial 
tearing). 
Mechanical Complications of MI
Ventricular Rupture 
PATOPHYSIOLOGY
Rupture can occur at almost any time after MI but is most 
common 3 to 7 days after infarction. It is at this point in the 
healing process that lysis of the myocardial connective tissue 
is maximal and the granulation tissue has not deposited 
sufficient collagenous matrix to buttress the wall. 
Mechanical Complications of MI
Left Ventricular Aneurysm
Left ventricular aneurysm (LVA) is defined as a localized area 
of myocardium with abnormal outward bulging and 
deformation during both systole and diastole. 
RISK FACTORS
- female sex
- total occlusion of the LAD artery
- single-vessel disease
- absence of previous angina. 
Mechanical Complications of MI
Left Ventricular Aneurysm
PATHOPHYSIOLOGY
A late complication, most commonly result from a large 
transmural anteroseptal infarct that heals with the formation 
of thin scar tissue. 
Complications of ventricular aneurysms include mural 
thrombus, arrhythmias, and heart failure, but rupture of the 
fibrotic wall does not occur 
Mechanical Complications of MI
Left Ventricular Failure and Cardiogenic Shock
 Left ventricular failure (pump failure) is defined as the 
condition in which cardiac output is insufficient to perfuse 
various body organs because of acute left ventricular 
contractile dysfunction caused by myocardial infarction 
 Cardiogenic shock clinically is defined as:
- Sustained systolic BP < 90 mmHg without hypovolemia, in 
combination with signs of organ severe, prolonged tissue 
hypoperfusion (e.g. oligiria, impaired consciousness) and 
signs of sympathetic activation (e.g. cool extremities, 
sweting)
PATOPHYSIOLOGY
 LV dysfunction results in low stroke volume reducing cardiac 
output. Myocardial perfusion is compromised by systemic 
hypotension and increased LV end-diastolic pressure
 Activation of compensatory mechanisms:
- Tachycardia (increases myocardial oxygen demand)
- Increased myocardial contractility in nondiseased myocardial  
segments
- Venoconstriction to increase effective circulating blood volume
- Neurohormonal (RAAS, vasopressin) activation lead to peripheral 
arterial vasoconstriction; although increasing peripheral 
resistance increases blood pressure, it also reduces tissue 
perfusion 
Mechanical Complications of MI
Left Ventricular Failure and Cardiogenic Shock
Arrhythmic Complications of MI
CLASSIFICATION
 Supraventricular tachyarrhythmias: sinus tachycardia, premature 
atrial contractions, paroxysmal supraventricular tachycardia, atrial 
flutter, and atrial fibrillation
 Accelerated junctional rhythms
 Bradyarrhythmias: sinus bradycardia and junctional bradycardia
 Atrioventricular (AV) blocks: first-degree AV block, second-degree AV 
block, and third-degree AV block
 Intraventricular blocks: left anterior fascicular block, right bundle 
branch block (RBBB), and left bundle branch block (LBBB)
 Ventricular arrhythmias: premature ventricular contractions (PVCs),
accelerated idioventricular rhythm, ventricular tachycardia, 
and ventricular fibrillation
 Reperfusion arrhythmias
Arrhythmic Complications of MI
PATOPHYSIOLOGY
 AMI is characterized by generalized autonomic dysfunction that 
results in enhanced automaticity of the myocardium and conduction 
system. Electrolyte imbalances (eg, hypokalemia and 
hypomagnesemia) and hypoxia further contribute to the development 
of cardiac arrhythmia. The damaged myocardium acts as substrate for 
re-entrant circuits, due to changes in tissue refractoriness.
 Enhanced efferent sympathetic activity, increased concentrations of 
circulating catecholamines, and local release of catecholamines from 
nerve endings in the heart muscle itself have been proposed to play 
roles in the development of peri-infarction arrhythmias. Furthermore, 
transmural infarction can interrupt afferent and efferent limbs of the 
sympathetic nervous system that innervates myocardium distal to the 
area of infarction. The net result of this autonomic imbalance is the 
promotion of arrhythmias.
Ischemic Complications of MI
Reccurent ischemia/reinfarction
 Recurrent postinfarction angina may be due to either an 
infarct extension or reinfarction in a separate territory or 
reocclusion of the infarction related artery 
 Postinfarction angina is important because it increases 
morbidity and mortality
Inflammatory Complications of MI
CLASSIFICATION
 Early pericarditis
 Late pericarditis (Dressler’s syndrome)
Inflammatory Complications of MI
Early Pericarditis
PATHOPHYSIOLOGY
 Usually develops within 24-96 after AMI. 
 Pericarditis (fibrinous or hemorrhagic) is caused by 
inflammation of pericardial tissue overlying infarcted 
myocardium. 
Inflammatory Complications of MI
Post-MI Syndrome (Dressler syndrome)
PATHOPHYSIOLOGY
 Symptoms of pericarditis occurring 2-3 weeks after AMI 
 The exact mechanism has yet to be elucidated, post-MI 
syndrome is considered to be an autoimmune process. 
Embolic
Left ventricular mural thrombus
Frequently develops after anterior infarcts of the LV wall.
LVMT is associated with a high risk of systemic embolization
(the most common clinical presentation is stroke ).
RISK FACTORS
- LV regional-wall akinesia or dyskinesia with blood stasis
- injury to and inflammation of the endocardial tissue that 
provides a thrombogenic surface
- a hypercoagulable state. 
Embolic
Left ventricular mural thrombus
PATHOPHYSIOLOGY
With any infarct, the combination of a local loss of contractility 
(causing stasis) with endocardial damage (causing a 
thrombogenic surface) can foster mural thrombosis 
PATIENT K.
65 y.o.
Complains 
 Burning central chest pain, more than 60 min
duration, without any radiation, nitroglycerine intake
doesn’t relief pain, abrupt onset, severity 7
 Dyspnea at rest, exacerbated by minimal physical 
exertion
Present illness
 Central chest pain and worsening symptoms of dyspnea had
been appeared abruptly, when the patient was at home and
carried out household chores
 Patient took nitroglycerine three times, but it did not relief pain
 After 30 min patient had called to emergency. ECG had been
recorded. Signs of STEMI of the posterior wall had been found
and patient had been delivered to cardiologic emergency
department
Past medical history
 Over 20 years patient suffer from essential hypertension. Patient
said that prescribed by cardiologist medications (ACE inhibitors,
diuretics and b-blockers) had been taken regularly, but BP level
had not been controlled properly (it occurred rising of BP to 160-
200/100 mm Hg)
 1999 year: Carotid artery atherosclerosis, left internal carotid
endarterectomy
 Since 2003 year bother persistent atrial fibrillation, tachysystolic
form, which was successfully converted to sinus rhythm by
pharmacologic cardioversion (IV amiodarone)
 25.02.2010 STEMI inferior wall complicated by cardiogenic
shock, Dressler’s syndrome
 06.12.2010 Ischemic stroke in the circle of Willis
Drug history
 Nebivalol 5 mg pd
 Losartan 50 mg pd
 Hydrochlorothiazide 25 mg pd
 Aspirin 75 mg pd
 Clopidogrel 75 mg pd
 Atorvastatin 20 mg pd
Allergies and reactions
 Patient has not any allergies
 Patient has not any reactions to drugs and 
medication
Alcohol and Smoking
 Alcohol consumption 1,5 L of normal beer per day = 
42 units of alcohol per week
 Smoking 1,5-2 packs per day during 40 years = 60-
80 pack-years
Family history
 Patient’s mother and brother suffer from essential 
hypertension
Inspection
VITAL SIGNS:
Temperature ̶ 36,8o C
PS ̶ 40 bpm
BP ̶ 110/60 mm Hg
Respiratory rate ̶ 17 pm
High ̶ 188 cm
Weight ̶ 105 kg
BMI ̶ 30,2 kg/m2
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Inspection
 Elderly male, has correct orientation in space and surroundings, 
mild depressed
 The posture is orthopnea (the patient uses 3 pillows)
 Skin is pale, mild cynosis of the lips, fingers and toes, rashes and
hemorrhages are absent
 Turgor and elasticity of the skin is decreased
 Subcutaneous fat tissue is increased, predominantly in
abdominal zone (central obesity, waist circumflex 138 cm)
 Nails are without any abnormalities
 Mucous membranes are pale and wet
 Tongue is clear and wet
 Severe oedema of the low extremities (3+)
 Lymph nodes are not palpable
 Joints are normal, active and passive movements are painless
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Inspection
 The head and neck examination is normal
 Carotid pulsation. JVP 6,5 cm above the sternal angle
 The chest is normal shape
 Decrease breath sounds and bibasilar coarse crackles of the
lungs to auscultation
 The point of apex beat is diffuse, 3 cm in diameter, shifted to
the left (palpated 1,5-2 cm to the left from medclavicular line in
the 5th intercostal space) 
 S1 and S2 are soft. Holosystolic murmur best heard at the
tricuspid valve
 Abdomen is soft and nontender. Hepatomegaly (+ 4 cm), liver
palpation is tender. The kidneys are not palpable
 Stool is normal
 Urination is normal
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Preliminary diagnosis
Coronary artery disease. Repeated myocardial infarction 
(28.08.2015). Postinfarction inferior wall cardiosclerosis 
(2006). Killip IV
Essential hypertension III stage, 2 grade
Persistent atrial fibrillation, tachysystolic form
ADDITIONAL RECOMMENDATIONS:
 Blood lipid profile 
 Coagulogram
 B-NP
 Coronary angiography
BASIC TESTS:
 Complete blood count
 Urinalysis
 Biochemical blood profile
(Glucose, Bilirubin, ALT, AST, 
Creatinine, Urea, Potassium, 
Total protein Cardiac Biomarkers)
 ECG
 Echocardiography
 Chest X-Ray
Plan of survey 
Clinical data
Complete blood count
28.08.2015
ESR 3 mm/h
Conclusion: Neutrophilic leucosytosis due to aseptic inflammatory 
response to the heart muscle necrosis 
WBC (N 4,0-9,0 10*9/L) 11,8 10*9/L
NE (N 1,7-7,7 10*9/L; 47,0-72% ) 9,1 10*9/L 77,8%
LY (N 0,4-4,4 10*9/L; 19,0-37,0%) 1,8 10*9/L 15,1%
MO (N 0,0-0,8 10*9/L; 3,0-11,0%) 0,7 10*9/L 6,1%
E (N 0,0-0,6 10*9/L; 0,5-5,0%) 0,1 10*9/L 0,5%
BA (N 0,0-0,2 10*9/L; 0,0-1,0%) 0,1 10*9/L 0,5%
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RBC (N 3,9-5,0 10*12/L) 4,39 10*12/L
Hb (N 120-160 g/L) 146 g/L
HCT (N 36,0-48,0%) 41,7 %
MCV (N 80-100 fL) 95,0 fL
MCH (N 28-36 pg) 33,3 pg
MCHC (N 310-370 g/L) 350 g/L
RDW-CV (N 10,0-16,5%CV) 14,0 %CV
PLT (N180-320 10*9/L) 172 10*9/L
PCT (N 0,1-1,0%) 0,14 %
MPV (N 5,0-10,0 fl) 8,3 fL
PDW (N 12,018,0%) 16,9 %
Clinical data
Urine analysis
28.08.2015
Conclusion: Mild proteinuria, less then 1,0 g/L; proteinuria is
associated with an increased risk of mortality from acute MI
Colour Light yellow
Specific gravity (N 1,001-1,040) 1,020
pH (N 5,0-7,0) 5.0
Protein (N absent) 0.068 g/L
Glucose (N absent) Absent
Eritrocytes (N single) 1-2/HPF
Leucocytes (N 6-8 in field) 8-10/HPF
Transitional epithelium (N single) sometimes
Tubular epithelium (N single) single
Hyliane casts (N single) 0-1/HPF
Granular casts (N absent) single
Crystals of oxalate (N absent) sometimes
Crystals of uric acid (N absent) sometimes
2
Clinical data
Biochemical blood profile
Glucose (3.9 - 6.4 venous blood)   ̶   4.1 mmol/L
 Conclusion: Hyperfermentemia (increased levels of AST, ALT) may be due to either 
acute MI and liver dysfunction.  Raised levels of cretinine, urea – signs of renal 
insufficiency. Hypokaliemia increases incidence of malignant ventricular arrhythmias . 
Hypoproteinemia may be due to either proteinuria and liver dysfunction.   
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28.08.2015
Bilirubin Total 
(N 17 - 21 mkmol/L)
9,98
mkmol/L
Bilirubin Direct 
(N 0 - 7,9 mkmol/L)
4,85
mkmol/L
Bilirubin Indirect
(N < 19 mkmol/L)
5,13
mkmol/L
ALT
(N < 41 U/L)
64,2 U/L
AST
(N < 35 U/L)
103,4 U/L
28.08.2015
Creatinine 
(N 62-106 mkmol/L)
424,97
mkmol/L
Urea
(N 3,0-9,2 mmol/L)
32,6 
mmol/L
Potassium
(N 3,5-5,1 mmol/L)
3,1 
mmol/L
Total Protein
(N 66-83 g/L)
48,4 g/L
Clinical data
Cardiac Biomarkers
Conclusion: Increased levels of cardiac enzymes (sign of damage to 
the cardiomyocytes)
28.09.2015 29.09.2015
13:30 19:00 01:00 7:00
CK-NAC (N < 190 U/l) 364.3 U/l 297.7 U/l 255.7 U/l 210.1 U/l
CK-MB (N 0-24 U/l) 68.83 U/l 63.8 U/l 44.48 U/l 33.72 U/l
Troponin I (N < 0.01 ng/ml )
12.94 
ng/ml
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Clinical data
ECG: Bradycardia, heart rate 40 bpm, junctional rhythm, LBBB (QRS 0.14 
ms), acute circular MI (ST elevation > 2 mm III, AVF, V1-V5, ST depression  
1 mm I, AVL). 
5
Clinical data
Ao D (20 – 37 mm) 39 mm EF (55 – 78 %) 46 %
AvO (17 – 26 mm) 16 mm FS (28 – 44 %) 23 %
LA (<38mm) 48 mm VST (6-11mm) 16,7 mm
MvO (28 mm) 25 mm RAD 57 mm
LV EDD (35 – 55 mm) 56,3 mm RVD (9 – 26 mm) 45,0 mm
LV ESD (28 – 33 mm) 43 mm RVAW (3 – 6 mm) 8 mm
LVPW (6 – 11 mm) 16,3mm
6TRANSTHORACIC ECHOCARDIOGRAM DATA 10.09.2015:
Sclerosis of aorta, aortic and mitral valve cusps. Mild valvular aortic stenosis. Aortic valve 
regurgitation I-II degree. Mitral valve regurgitation II degree. Tricuspid valve regurgitation I-II 
degree. Pulmonary artery valve regurgitation I degree. Dilation of all heart chambers. Left 
ventricle and right ventricle hepertrophy. Hypokinesia of the ventricular septa, basal and 
diaphragmal part of posterior wall, basal part of lateral wall of the left ventricle. 
Hydropericardium. Pulmonary hypertension I degree.
Conclusion: Signs of total heart failure with hypertrophy and dilation of heart chambers, 
valvular regurgitation, LV contractility reduction. Development of pulmonary hypertension. 
Hydropericardium. Hypokinesia of the LV posterior wall, which is affected by infarction. 
Clinical data
ULTRASOUND ABDOMEN
Diffuse increase echogenic density of liver 
Hepatomegaly: 
 vertical oblique size of the right lobe 165 mm (N<150 mm) 
 left lobe thickness 110 (N<65 mm)
V. Cava distension, liver congestion
Diffuse changes of echogenic density of the pancreas with normal organ’s 
size
Bilateral hydrothorax
Conclusion: diffuse alteration of liver and pancreatic parenchyma;
hepatomegaly; liver congestion, bilateral hydrothorax – signs of total 
congestive heart failure
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Clinical Diagnosis
MAIN DISEASE
Coronary artery disease. Acute repeated ST elevated circular
myocardial infarction (28.08.2015). Postinfarction inferior wall 
cardiosclerosis (2006). Killip IV
Essential hypertension III stage, 2 grade
Persistent atrial fibrillation, tachysystolic form
Risk score 4 (very high).
Chronic congestive heart failure II NYHA with the reduction of LV 
contractility
COMPLICATION
Junctional rhythm, bradycardia
Acute prerenal failure
CONCOMINANT DIAGNOSIS
Alcoholic liver disease
Course of Disease
30.08. 2015 7- 00
 Complains: black colored stools, fatigue, dizziness. 
 Inspection: T - 36,5 oC Pulse - 34 bpm
BP - 90/60 mm Hg Respiratory rate - 20 pm
Patient is drowsy and sluggish. Skin and mucous membranes are 
pale and dry. 
Bronchial breath sounds of the lungs to auscultation. Decrease 
breath sounds in bases. Rhonchi and crackles are not auscultated.
Pulse is regular, soft and small (pulsus filiformis). 
Soft S1 heart sound to auscultation. 
Abdomen is soft and tender in epigastric region. Hepatomegaly 
(+4cm), palpation is tender. The kidneys are not palpable.
1
Course of Disease
28.08.2015 01.09.2015
WBC (4,0-9,0 10*9/L) 11,8 10*9/L 12,5 10*9/L
NE (1,7-7,7 10*9/L; 47,0-72%) 9,1 10*9/L 77,8% 9,5 10*9/L 76,1%
LY (0,4-4,4 10*9/L; 19,0-37,0%) 1,8 10*9/L 15,1% 1,7 10*9/L 13,7%
MO (0,0-0,8 10*9/L; 3,0-11,0%) 0,7 10*9/L 6,1% 0,9 10*9/L 7,5%
E (0,0-0,6 10*9/L; 0,5-5,0%) 0,1 10*9/L 0,5% 0,3 10*9/L 2,2%
BA (0,0-0,2 10*9/L; 0,0-1,0%) 0,1 10*9/L 0,5% 0,1 10*9/L 0,5%
RBC (3,9-5,0 10*12/L ) 4,39 10*12/L 2,39 10*12/L
Hb (120-160 g/L) 146 g/L 76 g/L
HCT (36,0-48,0 ) 41,7% 23,1%
MCV (80-100 fL) 95,0 fL 96,7 fL
MCH (28-36 pg) 33,3 pg 31,8 Pg
MCHC (310-370 g/L) 350 g/L 329 gL
RDW-CV (10,0-16,5%CV) 14,0%CV 13,7 %CL
PLT (180-320 10*9/L) 172 10*9/L 183 10*9/L
PCT (0,1-1,0%) 0,14% 0,14 % 
MPV (5,0-10,0 fl) 8,3 fL 7,9 fL
PDW (12,0-18,0%) 16,9% 18,1%
Conclusion:
rapid significant 
decline level of 
RBC, Hb, and 
HCT – support 
acute GIT 
bleeding; minor 
increase level of 
leukocytes. 
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Course of Disease
FIBROSCOPY:  
‒ Esophagus is normal.
‒ Clear fluid present in the stomach. Mucosa is pale-pink.
‒ Several acute ulcers 0,5-0,8 cm in diameter, covered by fibrin is 
localized in antrum.
‒ Pylorus and duodenum are normal. 
Conclusion: Acute stomach ulcers.
3
Course of Disease
30.08. 2015  19-00
At patient took place respiratory arrest and cardiac arrest: 
absence of the breathing and pulsation of the main arteries, 
pupil dilation, loss of consciousness 
ECG-monitor: isoline
At patient developed CLINICAL DEATH
Emergency measures: 
 IV epinephrine
 Indirect cardiac massage
After 3 min emergency measures were successful: cardiac 
activity and respiration were restored
PS 80 bpm
BP 150/100 mmHg
RR 18 per min
4
Course of Disease
 In this case the most prominent atherosclerotic plaque is localized in the 
right coronary artery.  The right coronary artery distributes blood to right 
ventricle, right atrium, posterior portion of the interventricular septum, 
posterior wall of the left ventricle and the heart conduction system 
(including sinoatrial node). Ischemia of SA node may lead to its 
dysfunction (bradycardia, SA arrest, etc.) 
 Considering the severity of the patient's condition, refractory 
bradycardia (HR 40 bpm), developed acute renal failure and GIT 
bleeding, clinical death, 31.08.09, to improve patient’s condition, 
temporal pacemaker was implanted
5
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Course of Disease
DYNAMIC OF BODY TEMPERATURE
temporal pacemaker 
implantation
day of disease
Conclusion: seven days after pacemaker implantation fever has been
developed; temporal pacemaker implantation is predisposing factor to 
infection and infective endocarditis
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Course of Disease
03.09.2015 04.09.2015 25.09.2015
WBC (4,0-9,0 10*9/L) 10,0 10*9/L 12,2 10*9/L 12,7 10*9/L
NE (1,7-7,7 10*9/L; 47,0-72%) 6,8 10*9/L 69,2 % 10,2 10*9/L 84,1% 10,6 10*9/L 83,3 %
LY (0,4-4,4 10*9/L; 19,0-37,0%) 2,0 10*9/L 19,6 % 1,4 10*9/L 11,1% 1,3 10*9/L 10,6 %
MO (0,0-0,8 10*9/L; 3,0-11,0%) 0,7 10*9/L 6,8 % 0,4 10*9/L 2,9 % 0,5 10*9/L 3,6 %
E (0,0-0,6 10*9/L; 0,5-5,0%) 0,4 10*9/L 3,9 % 0,2 10*9/L 1,8 % 0,2 10*9/L 1,9 %
BA (0,0-0,2 10*9/L; 0,0-1,0%) 0,1 10*9/L 0,5 % 0,0 10*9/L 0,1 % 0,1 10*9/L 0,6 %
RBC (3,9-5,0 10*12/L ) 2,22 10*12/L 2.32 10*12/L 2,48 10*12/L
Hb (120-160 g/L) 70 g/L 73 g/L 76 g/L
HCT (36,0-48,0 ) 21,3 % 22,1 % 23,4 %
PLT (180-320 10*9/L) 184 10*9/L 134 10*9/L 102 10*9/L
ESR (1-10 mm/h) 7 mm/h 16 mm/h 7 mm/h
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DYNAMIC OF COMPLETE BLOOD COUNT 
Course of Disease
10.09.2015 14.09.2015 25.09.2015
WBC (4,0-9,0 10*9/L) 10,0 10*9/L 6,9 10*9/L 9,6 10*9/L
NE (1,7-7,7 10*9/L; 47,0-72%) 7,9 10*9/L 79,7 % 5,3 10*9/L 75,8% 8,2 10*9/L 84,4 %
LY (0,4-4,4 10*9/L; 19,0-37,0%) 1,3 10*9/L 13,2 % 1,0 10*9/L 14,1% 1,1 10*9/L 11,8 %
MO (0,0-0,8 10*9/L; 3,0-11,0%) 0,5 10*9/L 4,7 % 0,3 10*9/L 4,7 % 0,3 10*9/L 3,4 %
E (0,0-0,6 10*9/L; 0,5-5,0%) 0,2 10*9/L 1,7 % 0,3 10*9/L 4,8 % 0,0 10*9/L 0,2 %
BA (0,0-0,2 10*9/L; 0,0-1,0%) 0,1 10*9/L 0,7 % 0,0 10*9/L 0,6 % 0,0 10*9/L 0,2 %
RBC (3,9-5,0 10*12/L ) 2, 49 10*12/L 2.57 10*12/L 3,26 10*12/L
Hb (120-160 g/L) 77 g/L 79 g/L 98 g/L
HCT (36,0-48,0 ) 23,6 % 24,2 % 29,5 %
PLT (180-320 10*9/L) 111 10*9/L 119 10*9/L 465 10*9/L
ESR (1-10 mm/h) 18 mm/h 20 mm/h 13 mm/h
Conclusion: persistent neutrophilic leukocytosis, increased ESR – signs of 
inflammation; positive trend of anemia: rising amount of RBC, hemoglobin 
and hematocrit
DYNAMIC OF COMPLETE BLOOD COUNT 
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Course of Disease
Ao D (20 – 37 mm) 35,1 mm EF (55 – 78 %) 46 %
AvO (17 – 26 mm) 16,6 mm FS (28 – 44 %) 21 %
LA (<38mm) 53,2 mm VST (6-11mm) 16,4 mm
MvO (28 mm) 29,4 mm RAD 60,1 mm
LV EDD (35 – 55 mm) 55,4 mm RVD (9 – 26 mm) 45 mm
LV ESD (28 – 33 mm) 44,5 mm RVAW (3 – 6 mm) 7,9 mm
LVPW (6 – 11 mm) 16,8 mm
9TRANSTHORACIC ECHOCARDIOGRAM DATA 22.09.2015:
Sclerosis of aorta, aortic and mitral valve cusps. Aortic valve regurgitation II degree. Mild valvular 
aortic stenosis. Pathologic formation of the right coronary cusp of aortic valve (bacterial 
vegetation?). Mitral valve regurgitation II-III degree. Tricuspid valve regurgitation III degree. 
Pulmonary artery valve regurgitation I degree. Dilation of all heart chambers. Hydropericardium. 
Left ventricle and right ventricle hepertrophy. Hypokinesia of the ventricular septa, basal and 
diaphragmal part of posterior wall, basal part of lateral wall of the left ventricle. Pulmonary 
hypertension II degree.
Conclusion: Signs of total heart failure with hypertrophy and dilation of heart chambers, 
valvular regurgitation, LV contractility reduction. Development of pulmonary hypertension. 
Hydropericardium. Hypokinesia of the LV posterior wall, which is affected by infarction. The right 
coronary cusp of aortic valve bacterial vegetations.
Course of Disease
 CHEST X-Ray 22.09.2015:
Focal and infiltrative is not observed
Pulmonary venous hypertension
In both pleural cavities occurs minor amount of fluid
Heart is enlarged, left border is harshly displaced to the left
Aortic arch sclerosis
Conclusion: Pulmonary congestion. Bilateral hydrothorax. Cardiomegaly.
Absence of pulmonary seeding
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Course of Disease
BLOOD CULTURE
 23.09.2016 # 134 – negative
 25.09.2016 # 136 – negative
Conclusion: culture negative infective endocarditis may be due to 
prior administration of antibiotics 
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Course of Disease
DYNAMIC OF CARDIAC BIOMARKERS 
28.09.2015 13:30 19:00 01:00 7:00
CK-NAC (N < 190 U/l) 364.3 U/l 297.7 U/l 255.7 U/l 210.1 U/l
CK-MB (N 0-24 U/l) 68.83 U/l 63.8 U/l 44.48 U/l 33.72 U/l
Troponin I (N < 0.01 ng/ml ) 12.94 ng/ml
30.08.2015 31.08.2015
CK-NAC (N < 190 U/l) 125.5 U/l 120.9 U/l
CK-MB (N 0-24 U/l) 31.1 U/l 29.24 U/l
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28.09.2015 29.09.2015
13:30 19:00 01:00 7:00
CK-NAC (N < 190 U/l) 364.3 U/l 297.7 U/l 255.7 U/l 210.1 U/l
CK-MB (N 0-24 U/l) 68.83 U/l 63.8 U/l 44.48 U/l 33.72 U/l
Troponin I (N < 0.01 ng/ml )
12.94 
ng/ml
Conclusion: dynamic is positive, gradual decline of cardiac enzymes prove 
stabilization of heart necrosis
Course of Disease
DINAMIC OF BIOCHEMICAL PROFILE
28.08.
2015
30.08.
2015
02.09.
2015
03.09.
2015
07.09.
2015
09.09.
2015
10.09.
2015
14.09.
2015
Creatinine 
(N 62-106 mkmol/L)
424,97
mkmol/L
494,1
mkmol/L
120,99
mkmol/L
107,0
mkmol/L
116,0
mkmol/L
111,9
mkmol/
L
94,61
mkmol/L
74,77
mkmol/L
Urea
(N 3,0-9,2 mmol/L)
32,6 
mmol/L
28,4 
mmol/L
9,0 
mmol/L
9,8 
mmol/L
Potassium
(N 3,5-5,1 mmol/L)
3,1 
mmol/L
5,0
mmol/L
Total protein
(N 66-83 g/L)
48,4 
g/L
45,2 
g/L
49,0 
g/L
50,1
g/L
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Conclusion: positive dynamic in urea and creatinine, temporal pacemaker 
implantation improves kidney perfusion, acute renal failure abates; also occurs 
raising of total protein level; raising level of potassium: hypokalemia in the early 
phase of an acute MI is activation of the sympathetic nervous system leading to 
an influx of potassium from the extracellular to the intracellular body fluid 
compartment. 
Course of Disease
DYNAMIC OF LIVER TESTS AND ENZYMES
14
28.08.2015 02.09.2015 03.09.2015 07.09.2015 10.09.2015
Bilirubin Total 
(N 17 - 21 mkmol/L)
9,98
mkmol/L
13,53
mkmol/L
12,11
mkmol/L
14,87
mkmol/L
9,9
mkmol/L
Bilirubin Direct 
(N 0 - 7,9 mkmol/L)
4,85
mkmol/L
Bilirubin Indirect
(N < 19 mkmol/L)
5,13
mkmol/L
ALT
(N < 41 U/L)
64,2 U/L 74,64 U/L 80,0 U/L 46,6 U/L 31,4 U/L
AST
(N < 35 U/L)
103,4 U/L 96,5 U/L 56,0 U/L 42,5 U/L 29,2 U/L
Conclusion: positive dynamic in ASL and ALT levels, gradual decline        and 
further normalization 
Clinical syndromes
 ACUTE CORONARY SYNDROME
 ARTERIAL HYPERTENSION
 HEART FAILURE
 JUNCTIONAL RHYTHM
 INFLAMMATION
 RENAL FAILURE
 GASTROINTESTINAL BLEEDING
 HYPOPROTEINEMIA
 ANEMIA
 INFECTIVE ENDOCARDITIS
 OBESITY
ACUTE CORONARY SYNDROME
 Unstable angina
 ST segment elevation myocardial infarction (STEMI)
 Non ST segment elevation myocardial infarction (NSTEMI)
Clinical syndromes classification 1
Clinical syndromes classification
ARTERIAL HYPERTENSION (I)
Essential
Secondary:
I. Renal diseases
II. Endocrine hypertension
III. Hemodynamic hypertension:
IV. Neurogenic hypertension: 
V. Special forms: 
2
Clinical syndromes classification
ARTERIAL HYPERTENSION (III)
3
BP Classification 2007 ESC/ESH Guidelines for the management of Arterial Hypertension.  J Hypertens. 2007;25:1105-1187. 
Clinical syndromes classification
HEART FAILURE
 Acute heart failure 
 Chronic heart failure 
 Left sided heart failure 
 Right sided heart failure 
 Total heart failure 
 Heart failure with systolic dysfunction of left ventricle 
(EF less than 40%)
 Heart failure with diastolic dysfunction of left ventricle
(EF more than 50%)
 Heart failure with preserved function of left ventricle 
(EF more than 50%)
4
ACUTE HEART FAILURE
KILLIP CLASSIFICATION
CLASS I: No evidence of heart failure (mortality 6%)
CLASS II: Findings of mild to moderate heart failure (S3 gallop, 
rales less than half-way up lung fields or elevated
jugular venous pressure (mortality 17%)
CLASS III: Pulmonary edema (mortality 38%)
CLASS IV: Cardiogenic shock defined as systolic blood pressure
< 90 and signs of hypoperfusion such as oliguria, 
cyanosis, and sweating (mortality 67%) 
Clinical syndromes classification 5
Clinical syndromes classification
CHRONIC HEART FAILURE
6
Clinical syndromes classification
Patient:
- 65 years old
- smoker
- BP 160/90 
mmHg
Score 4 very 
high
European Heart Journal
7
Clinical syndromes classification
JUNCTIONAL RHYTHM
 P wave precede the QRS complex
 P wave follow the QRS complex
 P wave occur during the QRS complex
8
p-wave
p-wave
Clinical syndromes classification
Classification according to 
duration 
 Per-acute inflammation 
 Acute inflammation
 Sub-acute inflammation 
 Chronic inflammation 
Classification according to 
principle constituent of exudates
 Serous
 Catarrhal 
 Fibrinous 
 Suppurative (purulent) 
 Hemorrhagic 
 Lymophocytic 
INFLAMMATION
Classification according to etiology 
• Biological inflammation
• Chemical
• Physical 
• Immune factors  
• Classification according to location
• Localized 
• Widespread or Systemic
9
Clinical syndromes classification
RENAL FAILURE  (I)
ACUTE:
̶ Prerenal
̶ Intrinisic
̶ Obstructive
10
Clinical syndromes classification
RENAL FAILURE  (II)
 CHRONIC:
̶ Stage 1: Kidney damage with normal or increased GFR 
(>90 mL/min/1.73 m2)
̶ Stage 2: Mild reduction in GFR (60-89 mL/min/1.73 m 2)
̶ Stage 3: Moderate reduction in GFR (30-59 mL/min/1.73 m 2)
̶ Stage 4: Severe reduction in GFR (15-29 mL/min/1.73 m 2)
̶ Stage 5: Kidney failure (GFR < 15 mL/min/1.73 m 2 or dialysis)
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Clinical syndromes classification
GASTROINTESTINAL BLEEDING (I)
 According to localization:
‒ Upper gastrointestinal bleeding
‒ Lower gastrointestinal bleeding
 According to the duration:
‒ Acute
‒ Chronic 
 According to functional state:
‒ Compesated
‒ Decompesated
 According to the intensity:
‒ Profuse bleeding
‒ Occult bleeding
12
Clinical syndromes classification
GASTROINTESTINAL BLEEDING (II)
ETIOLOGY
13
 Lower gastrointestinal bleeding
‒ Hemorrhoids
‒ Cancer
‒ Angiodysplasia
‒ Ulcerative colitis
‒ Crohn's disease
‒ Angiodysplasia
‒ Diverticulosis / diverticulitis
 Upper gastrointestinal bleeding
‒ Esophagitis and gastroesophageal 
reflux disease
‒ Mallory-Weiss tear
‒ Varices (portal hypertensive 
gastropathy)
‒ Peptic ulcer
‒ Acute stress gastritis
‒ Cancer of the stomach 
‒ Angiodysplasia 
Other causes:
‒ Celiac disease
‒ Hemolysis
‒ Myopathy
‒ Excessive physical 
‒ Heperthyrosis
‒ Metabolic sundrome
‒ Diabetes mellitus
‒ Myocardial infarction
‒ Ischemic heart disease 
‒ Congestive heart failure
Liver diseases:
‒Cirrhosis
‒Viral hepatitis acute and chronic
‒Nonalcoholic steatohepatitis
‒Alcoholic liver disease
‒Medications and toxins
‒Autoimmune hepatitis
‒Hemochromatosis
‒Cystic fibrosis
‒Wilson disease
Clinical syndromes classification
CYTOLYSIS
CAUSES
14
Clinical syndromes classification
HYPOPROTEINEMIA
 Protein-losing gastroenteropathy: pancreatic dysfunction, 
bacterial overgrowth in the small intestine, gastrointestinal
infection, parasite infestations, diarrhea, Crohn's disease, 
ulcerative colitis, small intestine resection, AIDS, cancer
 Malnutrition
 Liver disease
 Renal disease (nephrotic syndrome)
 Sepsis
15
Clinical syndromes classification
ANEMIA
ETHIOLOGIC CLASSIFICATION
I. IMPAIRED PRODUCTION
 Disturbance of proliferation and
maturation of erythroblasts
‒ Pernicious anemia
‒ Vitamin B12 deficiency anemia
‒ Anemia of folic acid deficiency
‒ Anemia of prematurity
‒ Iron deficiency anemia
‒ Thalassemias
‒ Congenital dyserythropoietic
anemias
‒ Anemia of renal failure
 Other mechanisms of impaired
RBC production
‒ Myelophthisic anemia
‒ Myelodysplastic syndrome
‒ Anemia of chronic inflammation
 Disturbance of proliferation and
differentiation of stem cells
‒ Pure red cell aplasia
‒ Aplastic anemia
‒ Anemia of renal failure
‒ Anemia of endocrine disorders
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Clinical syndromes classification
 Intrinsic (intracorpuscular) 
abnormalities
 Hereditary elliptocytosis
 Hereditary spherocytosis
 Abetalipoproteinemia
 Enzyme deficiencies
‒ Pyruvate
kinase and hexokinase deficiencies
‒ Glucose-6-phosphate 
dehydrogenase
deficiency and glutathione
synthetase deficiency
 Hemoglobinopathies
‒ Sickle cell anemia
‒ Hemoglobinopathies causing
unstable hemoglobins
 Paroxysmal nocturnal hemoglobinuria
17
ANEMIA
ETHIOLOGIC CLASSIFICATION
II. INCREASED DESTRUCTION (HEMOLYTIC ANEMIAS)
 Extrinsic (extracorpuscular) 
abnormalities
 Antibody-mediated
‒ Warm autoimmune hemolytic
anemia
‒ Cold agglutinin hemolytic anemia
‒ Rh disease
‒ Transfusion reaction to blood
transfusions
 Mechanical trauma to red cells
‒ Microangiopathic hemolytic
anemias
‒ intravascular coagulation
‒ Infections, including malaria
‒ Heart surgery
‒ Haemodialysis
Clinical syndromes classification
ANEMIA
III. BLOOD LOSS
 Anemia of prematurity
 Trauma or surgery
 Gastrointestinal tract lesions
 Gynecologic disturbances
 Infection by intestinal nematodes
IV. FLUID OVERLOAD
 Excessive sodium or fluid intake, sodium or water retention and
fluid shift into the intravascular space
 Anemia of pregnancy
18
Clinical syndromes classification
ANEMIA
HEMOGLOBIN LEVEL CLASSIFICATION
 Mild              - Hb 90 – 120 g/L
 Moderate     - Hb 70 – 90 g/L 
 Severe         - Hb <70 g/L
19
Clinical syndromes classification
INFECTIVE ENDOCARDITIS
Duration
 Acute bacterial endocarditis 
 Subacute bacterial endocarditis 
Culture results
 Culture-positive
 Culture-negative 
Valve type
 Native-valve endocarditis
 Prosthetic-valve endocarditis 
20
http://dx.doi.org/10.1093/eurheartj/ehp2852369-2413 First published online: 27 August 2009
Clinical syndromes classification
INFECTIVE ENDOCARDITIS
21
INFECTIVE ENDOCARDITIS
http://dx.doi.org/10.1093/eurheartj/ehp2852369-2413 First published online: 27 August 2009
Clinical syndromes classification 22
Clinical syndromes classification
INFECTIVE ENDOCARDITIS
The Duke diagnostic criteria
Major blood culture criteria for IE include the following:
 Two blood cultures positive for organisms typically found in patients with IE
 Blood cultures persistently positive for one of these organisms, from cultures 
drawn more than 12 hours apart
 Three or more separate blood cultures drawn at least 1 hour apart
Major echocardiographic criteria include the following:
 Echocardiogram positive for IE, documented by an oscillating intracardiac 
mass on a valve or on supporting structures, in the path of regurgitant jets, 
or on implanted material, in the absence of an alternative anatomic 
explanation
 Myocardial abscess
 Development of partial dehiscence of a prosthetic valve
 New-onset valvular regurgitation
23
Clinical syndromes classification
INFECTIVE ENDOCARDITIS
The Duke diagnostic criteria
Minor criteria for IE include the following:
 Predisposing heart condition or intravenous drug use
 Fever of 38°C (100.4°F) or higher
 Vascular phenomenon, including major arterial emboli, septic pulmonary 
infarcts, mycotic aneurysm, intracranial hemorrhage, conjunctival 
hemorrhage, or Janeway lesions
 Immunologic phenomenon such as glomerulonephritis, Osler nodes, Roth 
spots, and rheumatoid factor
 Positive blood culture results not meeting major criteria or serologic 
evidence of active infection with an organism consistent with IE
 Echocardiogram results consistent with IE but not meeting major 
echocardiographic criteria
24
Clinical syndromes classification
INFECTIVE ENDOCARDITIS
The Duke diagnostic criteria
DEFINITE IE
 Pathologic criteria
Microorganism: demonstrated by culture or histology in a vegetation, or in a vegetation that has 
embolized, or in an intracardiac abacess  OR
Pathologic lesions: vegetation or intracardiac abacess, confirmed by histology, showing active 
endocarditis
 Clinical criteria
2 major criteria  OR
1 major criteria and 3 minor criteria   OR
5 minor criteria 
POSSIBLE IE
Findings consisting with IE that fall short of “DEFINITE IE” but not rejected:
1 major criteria and 2 minor criteria OR
3 minor criteria 
REJECTED IE
Firm alternate diagnosis for manifestations of endocarditis  OR
Resolution of manifestation of endocarditis, with antibiotic therapy for four days or less  OR
No pathologic evidence of IE at a surgery or autopsy after antibiotic therapy for four days or less 
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Clinical syndromes classification
OBESITY
BMI (kg/m2) Classification
from up to
18.5 underweight
18.5 25.0 Normal weight
25.0 30.0 overweight
30.0 35.0 class I obesity
35.0 40.0 class II obesity
40.0 class III obesity
26
COMPLICATION
Junctional rhythm, bradycardia (40 bpm)
Acute prerenal failure
Clinical death (30.08.2015)
Temporal pacemaker implantation (31.08.2015)
Possible nasocomial active device-related (temporal pacemaker) infective endocarditis
Acute gastric stress ulcers, GIT bleeding
Anemia of blood loss, moderate
Final Diagnosis
MAIN DISEASE
Coronary artery disease. Repeated ST elevated circular myocardial infarction 
(28.08.2015). Postinfarction inferior wall cardiosclerosis (2006). Killip IV
Essential hypertension III stage, 2 grade
Persistent atrial fibrillation, tachysystolic form
Chronic heart failure with systolic dysfunction of left ventricle
Risk score 4 (very high).
CONCOMINANT DIAGNOSIS
Alcoholic liver disease, alcoholic hepatitis
Obesity class I
Management
LIFESTYLE MODIFICATION: 
 Diet: low in saturated fat and high in omega-3 fat, low carbohydrates, 
low sodim (3g/d)
 Limit alcohol consumption
 Body weight control: goal BMI 18,5 - 24,99 
 Smoking cessation
1
Management
ACUTE CORONARY SYNDROME MANAGEMENT
STEMI
Emergent PCI available within 90 min
NO                                YES 
Fibrinolytic                   Primary PCI
therapy                        (PTCA)    
(e.g. streptokinase,              CABG 
alteplase, tenecteplase,
reteplase)
2
Management
ACUTE CORONARY SYNDROME MANAGEMENT
General measures: Pain control (morphine)
Supplemental oxygen (if needed) 
Antithrombotic therapy:
Antiplatelet agents        Aspirin
Clopidogrel (prasugrel)
GB IIb/IIIa inhibitor
Anticoagulants          LMWH (enoxaparin)
Unfractioned IV heparin
Fondaparinux
Bivalirudin (only if undergoing PCI)
Anti-ischemic therapy:  B-blocker 
Nitrates
Ca channel blocker (verapamil, diltiazem, 
nifedipine, amlodipine, felodipine)
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Management
ACUTE CORONARY SYNDROME MANAGEMENT
Adjunctive therapy: Statin (lovastatin, simvastatin, pravastatin, 
fluvastatin, otorvastatin, rosuvastatin )
ACE inhibitor (captopril, ramipril, enalapril, 
quinapril, perindopril, lisinopril, benazepril)
Aldosterone blockers(spironalocton, eplerenon)
Proton pomp inhibitor (omeprazole)
Rehabilitation
Education
Counseling
4
Management
ACUTE CORONARY SYNDROME TREATMENT
 IV Morphine sulfate
Low molecular weight heparin (enoxaparinum 80 mg/2d)
Aspirin 75 mg/d
Clopidogrel 75 mg/d
Otorvastatin 80 mg/d
Eplerenonum 25 mg/d
Ramipril 2,5 mg/d
Pantoprasol 40 mg/d
ADDITIONALLY
Thrombolytic therapy (IV Alteplase)  or       
■ PCI
5
Management
BRADYCARDIA TREATMENT
Atropine IV/IM
Transcutaneous pacing
6
Management
BRADYCARDIA TREATMENT
 Refractory bradycardia requires implantation of 
temporal pacemaker
7
Management
INFECTIVE ENDOCARDITIS TREATMENT
http://dx.doi.org/10.1093/eurheartj/ehp285 2369-2413 First published online: 27 August 2009 
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Management
INFECTIVE ENDOCARDITIS TREATMENT
Staphylococci are the most frequent pathogens, S. aureus being 
predominant in the acute forms of pacemakers infection. 
(Klug D, Lacroix D, Savoye C, Goullard L, Grandmougin D, Hennequin JL, Kacet S, Lekieffre J. Systemic infection related to endocarditis on 
pacemaker leads: clinical presentation and management. Circulation1997;95:2098-2107. )
 Pacemaker removal 
 IV Cefepime 1,0 g 2 times/d         14 days
 IV Vancomycin 2 g 1 times/d        7 days
9
Management
RENAL FAILURE TREATMENT
 Supportive treatment
Measures to correct underlying causes of acute kidney injury
Maintenance of volume homeostasis and correction of 
biochemical abnormalities remain the primary goals of 
treatment and may include the following measures:
- Correction of fluid overload with furosemide
- Correction of severe acidosis with bicarbonate administration, 
which can be important as a bridge to dialysis
- Correction of hyperkalemia
 Renal replacement therapy
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Management
RENAL FAILURE TREATMENT
Reduction of cardiac output due to myocardial infarction and 
bradicardia due to sinoatrial ischemia, hypovolemia due to GI 
bleeding lead to prerenal acute kidney injury
Temporal pacemaker implantation improves cardiac output and 
kidney perfusion
IV solutions to increase blood volume is not indicated, because of  
increasing heart preload and heart demands
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Management
GASTROINTESTINAL BLEEDING TREATMENT
 Therapeutic endoscopy (injection of epinephrine or 
sclerosants, electrocoagulation, application of hemoclips or 
endoclips, etc.)
 Proton pomp inhibitors ( omeprazole, pantoprazole and 
esomeprazole)
 Histamine receptor antagonists (famotidine)
 Surgical treatment
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Management
GASTROINTESTINAL BLEEDING TREATMENT
Withhold:
Low molecular weight heparin
Aspirin 
Clopidogrel.
Prescribe: 
‒Hemostatic therapy:
IV ε-aminocaproic acid 100,0 2 times/d 
IV Etamsilate 12,5% 4,0 3 times/d 
IV Menadione 1% 1,0 3 times/d 
‒Antisecretory drugs
IV Famotidine 20 mg 2 times/d 
IV Pantoprazole 40 mg 1 time/d 
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Management 14
ANEMIA TREATMENT
- Transfusion of packed red blood cells 
- Iron supplementation (ferrous sulfate )
- Diet
Management 15
ANEMIA TREATMENT
 Ferrous sulfate - 60 mg/d per os for 3 months
 Folic acid 400 mcg/day per os for 3 months
Management
ALCOHOLIC LIVER DISEASE TREATMENT
Essential phospholipids - 300 mg/ 2d for 3 months
Argininum - 1,5 g/ 2d for 3 months
16
Prognosis
 Prognosis for recovery: 
Unfavorable
 Prognosis for life:
At this stage of disease take place irreversible structural heart
changes (post MI heart remodeling and heart chamber dilation). 
At the present time main goal of the therapy is prevention
further progression of congestive heart failure and improvement
patient’s life quality.
Finale
 We illustrate a case report that demonstrates complicated 
myocardial infarction and remind clinicians that prompt 
recognition and management are critical in this uncommon 
grave clinical case
 Clinicians must keep potentially lethal complications in 
mind when evaluating these unstable patients
 Early, aggressive, and judicious treatment of these 
complications may substantially decrease the morbidity and 
mortality associated with acute myocardial infarction
